Business Description
Sage Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US78667J1088
Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 145.83 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.8 | |||||
| Beneish M-Score | 6.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -59 | |||||
| 3-Year Book Growth Rate | -27.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 57.11 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.94 | |||||
| 9-Day RSI | 16.2 | |||||
| 14-Day RSI | 21.46 | |||||
| 6-1 Month Momentum % | 1.99 | |||||
| 12-1 Month Momentum % | -54.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.51 | |||||
| Quick Ratio | 10.51 | |||||
| Cash Ratio | 9.1 | |||||
| Days Payable | 2093.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | 0.72 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 97.5 | |||||
| Operating Margin % | -631.98 | |||||
| Net Margin % | -626.32 | |||||
| FCF Margin % | -625.91 | |||||
| ROE % | -54.3 | |||||
| ROA % | -49.3 | |||||
| ROIC % | -1107 | |||||
| ROC (Joel Greenblatt) % | -5459.29 | |||||
| ROCE % | -54.7 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.54 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.14 | |||||
| EV-to-EBIT | -0.32 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Forward-EBITDA | -1.88 | |||||
| EV-to-Revenue | 2 | |||||
| EV-to-Forward-Revenue | 3.13 | |||||
| EV-to-FCF | -0.33 | |||||
| Price-to-Net-Current-Asset-Value | 1.16 | |||||
| Price-to-Net-Cash | 1.36 | |||||
| Earnings Yield (Greenblatt) % | -312.5 | |||||
| FCF Yield % | -59.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SAGE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sage Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 86.456 | ||
| EPS (TTM) ($) | -9.05 | ||
| Beta | 0.26 | ||
| Volatility % | 61.69 | ||
| 14-Day RSI | 21.46 | ||
| 14-Day ATR ($) | 0.845868 | ||
| 20-Day SMA ($) | 17.741 | ||
| 12-1 Month Momentum % | -54.58 | ||
| 52-Week Range ($) | 15.06 - 59.99 | ||
| Shares Outstanding (Mil) | 60.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sage Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sage Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sage Therapeutics Inc Frequently Asked Questions
What is Sage Therapeutics Inc(SAGE)'s stock price today?
The current price of SAGE is $15.24. The 52 week high of SAGE is $59.99 and 52 week low is $15.06.
When is next earnings date of Sage Therapeutics Inc(SAGE)?
The next earnings date of Sage Therapeutics Inc(SAGE) is 2024-05-02 Est..
Does Sage Therapeutics Inc(SAGE) pay dividends? If so, how much?
Sage Therapeutics Inc(SAGE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers